Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-035225
Filing Date
2024-08-06
Accepted
2024-08-06 16:26:06
Documents
94
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q aqst-20240630.htm   iXBRL 10-Q 1362092
2 EX-31.1 q22024ex311.htm EX-31.1 10879
3 EX-31.2 q22024ex312.htm EX-31.2 11095
4 EX-32.1 q22024ex321.htm EX-32.1 6375
5 EX-32.2 q22024ex322.htm EX-32.2 6441
  Complete submission text file 0001628280-24-035225.txt   8132991

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20240630.xsd EX-101.SCH 65569
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aqst-20240630_cal.xml EX-101.CAL 69655
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aqst-20240630_def.xml EX-101.DEF 373760
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20240630_lab.xml EX-101.LAB 750529
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20240630_pre.xml EX-101.PRE 575753
96 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20240630_htm.xml XML 968155
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38599 | Film No.: 241179735
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)